Posttransplant lymphoproliferative disorder is a serious complication following solid organ as well as hematopoietic stem cell transplantation due to prolonged immunosuppressive therapy. Plasmablastic lymphoma, although classically associated with HIV infection, has since been described in transplant patients as a variant of posttransplant lymphoproliferative disorder with varying clinical presentations. Here we add two additional cases to the literature: one following lung transplantation and one following pancreatic transplantation. In addition, the demographic, therapeutic, and immunophenotypic characteristics from prior reported cases are summarized. P lasmablastic lymphoma was fi rst described in 1997 as an oral mucosal lesion associated with HIV-positive individuals as a subtype of diff use large cell lymphoma (1, 2) . Since its initial description, it has now become well established as an entity seen in HIV-negative individuals as well, albeit rarely (3) . In 2003, the fi rst case of plasmablastic lymphoma in a posttransplant lymphoproliferative disorder (PTLD) was reported as a cutaneous leg ulcer (4) . Since this original description, several additional cases have been reported following various solid organ and bone marrow transplantations. We present two cases of plasmablastic lymphoma, one following lung transplantation with subsequent immunosuppressive therapy (previously reported in the context of unusual clinical fi ndings) (5) and another following pancreatic transplantation.
CASE 1
A 67-year-old man with idiopathic pulmonary fi brosis diagnosed at age 63 (2008) underwent sequential bilateral lung transplantation in October 2011. Th e patient had a complicated clinical course thereafter with repeated episodes of respiratory failure requiring reintubation and eventual tracheostomy. He subsequently developed bilateral pulmonary infi ltrates and was placed on antibiotics. Biopsy showed acute lung injury, and the patient was placed on high-dose steroids for presumed acute rejection. Th e patient's respiratory status continued to decline, and he developed worsening pulmonary infi ltrates. Repeat biopsy again showed acute lung injury with organization. He was again treated with high-dose corticosteroids as well as a 10-day trial of antithymocyte globulin (Atgam) for possible rejection. Th e patient began to recover clinically, and at the time of his discharge 45 days later, he was breathing room air and his tracheostomy site was healing. To modulate his posttransplant immune function, the patient was treated with tacrolimus, prednisone, and azathioprine.
In February 2012, the patient presented with facial swelling, numbness, right lower lip swelling, and mild erythema within the inner lip with corresponding numbness. He had macrocytic anemia with normal folate and vitamin B12 levels. Brain magnetic resonance imaging revealed multifocal patchy regions of marrow signal abnormality involving the calvaria, skull base, and visualized upper cervical spine. He had elevated copies of Epstein-Barr virus (EBV). Histologic analysis of a bone marrow biopsy specimen disclosed scattered cellular sheets of a plasmacytoid infi ltrate composed of medium-to large-sized cells with an abundant amount of basophilic cytoplasm, eccentrically located nuclei with a clock-faced chromatin, and a perinuclear hof. Many malignant cells displayed a large central nucleolus with fi nely dispersed immature chromatin consistent with a "plasmablast"-type morphology (Figures 1 and 2) . Occasional cells showed bi-and trinucleated forms, and mitotic activity was increased with many atypical fi gures seen.
Immunophenotypically, these cells were characterized by strong immunohistochemical staining to CD138 with patchy membranous positivity seen with CD56. CD30 and CD20 were negative in the plasmacytoid cells. Most malignant infi ltrates were negative for both kappa and lambda in situ hybridization with rare scattered cells showing positivity. Additionally, most cells stained positively for EBV early RNA (EBER) by in situ hybridization (Figure 2 ). After a diagnosis of posttransplant plasmablastic lymphoma was made, the patient was started on a cyclophosphamide, hydroxydaunorubicin, vincristine (Oncovin), and prednisone/ prednisolone (CHOP) chemotherapy regimen. After 1 cycle of treatment, the patient elected to receive palliative care only.
CASE 2
In 2008, a 45-year-old woman received a pancreas transplant for brittle diabetes mellitus type I. Over the next year, the patient was hospitalized multiple times with abdominal pain, which was attributed to pancreatitis. In May 2009, the patient was hospitalized for abdominal pain, again with a failed pancreatic transplant. She underwent a planned pancreatectomy. During the procedure, a 16-cm loop of small bowel was identifi ed wrapping around a 6.0 × 5.0 × 4.0 cm soft tissue mass within the abdomen, and it was resected.
Histomorphologically, the mass was composed of large round to oval-shaped cells with fi nely dispersed immature chromatin and prominent nucleoli consistent with a "blast"-type morphology (Figure 3) . Immunohistochemically, the cells had a positive stain for CD138 and CD56 and were positive for EBER by in situ hybridization, confi rming the diagnosis of plasmablastic lymphoma. Postoperatively, the patient had a complicated course and died 7 days following the procedure due to overwhelming gram-negative sepsis.
DISCUSSION
PTLD is a heterogenous disease seen in patients who have undergone solid organ or hematopoietic stem-cell transplantation. It was fi rst described in 1968 in association with renal transplantation. In patients who have received a transplant, the risk of lymphoma is increased 20% to 120% compared with the general population (6) . Additionally, several risk factors have been shown to increase the risk of PTLD, including immunosuppression (6-8), EBV (9-12), genetic susceptibility (13) , and a host of other miscellaneous factors including Caucasian race (14) , hepatitis C, cytomegalovirus, and human herpes virus-8 infection (15) (16) (17) . PTLD is classifi ed into four categories based on immunophenotype, morphology, and molecular criteria. Th ese include early lesions, polymorphic, monomorphic, and classical Hodgkin lymphoma (18) .
Traditionally, plasmablastic lymphomas have been described in HIV-positive individuals, typically occurring in the mucosa of the oral cavity. Th e lesion is characterized morphologically by blastic cells with a plasma cell immunophenotype. In recent years, this entity has also been described in individuals who have previously undergone a transplantation procedure, including kidney, heart, heart/lung, liver/small bowel, and bone marrow ( Table 1 ) (4, (19) (20) (21) (22) (23) (24) . To our knowledge, the present report is the fi rst describing plasmablastic lymphoma following pancreatic transplantation.
Morphologically, PTLD plasmablastic lymphoma is characterized by larger immature cells with abundant cytoplasm, nucleoli, and an open chromatin pattern. Immunophenotypically ( Table 2) , previously reported cases have been predominantly positive for CD138 and VS38 and usually display either a kappa or lambda restriction. B-cell markers, such as CD20 and CD79a, are typically negative, and the proliferative index (Ki-67) is invariably high, usually above 80%. Th e preponderance of reports demonstrates positivity for EBER through in situ hybridization, with one other case demonstrating an EBV and human herpes virus-8 coinfection (20) . Th e role of EBV in the development of PTLDs (including plasmablastic lymphoma) is well established. EBV preferentially infects B cells, where its genome can lay dormant as an episome (25) . In healthy immunocompetent individuals, activated T cells play an important role in controlling the proliferation and elimination of infected B cells. Due to immunosuppressive therapy severely impairing T-cell activity, immunosuppressed patients are at risk for uncontrolled proliferation of the infected B cells.
Th e treatment for PTLD has many modalities with varying degrees of eff ectiveness. Antiviral therapies, particularly ganciclovir, have been used as prophylactic agents to prevent EBV-related PTLD, although the data are not defi nitive. Donor-derived EBV-specifi c cytotoxic T-cell lymphocyte infusions (adoptive immunotherapy) have also been shown to play a role in PTLD prophylaxis in both adult and pediatric populations (26, 27) . Treatment modalities of diagnosed PTLD have included reduced immunosuppression as well as CHOP-based chemotherapy with or without rituximab. A recent study looking at treatment options for PTLD plasmablastic lymphoma by Zimmermann et al found that immunosuppression with systemic chemotherapy (CHOP-21) achieved a more lasting and complete remission than immunosuppression with local therapy (24) .
